Literature DB >> 10699340

Inactivated meningococci and pertussis bacteria are immunogenic and act as mucosal adjuvants for a nasal inactivated influenza virus vaccine.

A K Berstad1, S R Andersen, R Dalseg, S Dromtorp, J Holst, E Namork, E Wedege, B Haneberg.   

Abstract

Whole killed meningococci (Nm) and pertussis bacteria (Bp) were tested for mucosal immunogenicity and as mucosal adjuvants for an inactivated influenza virus vaccine given intranasally to unanaesthetized mice. Virus was given alone, or simply mixed with one of the bacterial preparations, in four doses at weekly intervals. The virus alone induced low but significant increases of influenza-specific IgG antibodies in serum measured by ELISA, whereas IgA responses in serum and saliva were insignificant compared to non-immunized controls. With Bp or Nm admixed, serum IgG and IgA and salivary IgA responses to the influenza virus were substantially augmented (P<0.005). However, this adjuvant effect of the bacterial preparations was not significant for responses in the intestine as measured by antibodies in faeces. Antibody responses to Bp itself, but not to Nm, were inhibited by the admixture of the virus vaccine. Moreover, the pertussis preparation induced salivary antibodies which cross-reacted with Nm. Whole-cell bacteria with inherent strong mucosal immunogenicity may also possess mucosal adjuvanticity for admixed particulate antigens which are weakly immunogenic by the nasal route.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10699340     DOI: 10.1016/s0264-410x(99)00442-9

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Orally administered Giardia duodenalis extracts enhance an antigen-specific antibody response.

Authors:  L A Dunn; J A Upcroft; E V Fowler; B S Matthews; P Upcroft
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

2.  The respiratory microbiota: associations with influenza symptomatology and viral shedding.

Authors:  Kyu Han Lee; Betsy Foxman; Guillermina Kuan; Roger López; Kerby Shedden; Sophia Ng; Angel Balmaseda; Aubree Gordon
Journal:  Ann Epidemiol       Date:  2019-07-31       Impact factor: 3.797

3.  Controlled inflammatory responses in the lungs are associated with protection elicited by a pneumococcal surface protein A-based vaccine against a lethal respiratory challenge with Streptococcus pneumoniae in mice.

Authors:  Fernanda A Lima; Daniela M Ferreira; Adriana T Moreno; Patrícia C D Ferreira; Giovana M P Palma; Jorge M C Ferreira; Isaias Raw; Eliane N Miyaji; Paulo L Ho; Maria Leonor S Oliveira
Journal:  Clin Vaccine Immunol       Date:  2012-07-03

4.  Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae.

Authors:  Carolina Salcedo-Rivillas; Anne-Sophie Debrie; Eliane Namie Miyaji; Jorge M C Ferreira; Isaías Raw; Camille Locht; Paulo L Ho; Nathalie Mielcarek; Maria Leonor S Oliveira
Journal:  Clin Vaccine Immunol       Date:  2014-05-07

5.  Influence of intravenous anesthesia on mucosal and systemic antibody responses to nasal vaccines.

Authors:  Libuse Janakova; Hilde Bakke; Inger Lise Haugen; Aud K H Berstad; E Arne Høiby; Ingeborg S Aaberge; Bjørn Haneberg
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

6.  Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice.

Authors:  Maria Leonor S Oliveira; Eliane N Miyaji; Daniela M Ferreira; Adriana T Moreno; Patricia C D Ferreira; Fernanda A Lima; Fernanda L Santos; Maria Aparecida Sakauchi; Célia S Takata; Hisako G Higashi; Isaías Raw; Flavia S Kubrusly; Paulo L Ho
Journal:  PLoS One       Date:  2010-05-27       Impact factor: 3.240

7.  Lysine: Is it worth more?

Authors:  D Datta; A Bhinge; V Chandran
Journal:  Cytotechnology       Date:  2001-07       Impact factor: 2.058

Review 8.  The Role of Mucosal Immunity in Pertussis.

Authors:  Luis Solans; Camille Locht
Journal:  Front Immunol       Date:  2019-01-14       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.